Skip Navigation

Newsroom

Project BioShield Annual Report to Congress:  August 2006 through July 2007 Released

During the current reporting period, HHS engaged in substantial BioShield-enabled acquisition activities (a) to award a contract for acquisition of Modified Vaccinia Ankara (MVA) smallpox vaccine, (b) to initiate a sole-source acquisition of additional Anthrax Vaccine Adsorbed (AVA); and (c) to pursue acquisition both of recombinant protective antigen (rPA) vaccine for anthrax, and of therapeutics to mitigate or treat neutropenia associated with acute radiation syndrome (ARS).

Learn More >>

 

Medical Planning and Countermeasures 

Learn More >>

In The Spotlight

Operations and Training

Learn More >>

Communicating in a Crisis

Learn More >>

News In Pictures

Learn More >>